FARMINGDALE, N.Y., Aug. 10, 2011 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), a medical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for wound debridement, spinal surgery, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications, has announced its immediate entry into surgical wound debridement by adding their SonicOne® technology to the BoneScalpel™ surgical platform. The BoneScalpel with SonicOne Technology is designed for surgical wound debridement and is an updated and expanded version of the Company's existing BoneScalpel product. The SonicOne Wound Debridement System has been marketed by the Company to free-standing wound clinics, hospital-based wound clinics, and long term acute care hospitals for several years.
Misonix's has completed product training with its domestic sales force on the BoneScalpel with SonicOne Technology; training of its international distributors is scheduled on a country by country basis over the next several months. Reimbursement is available for surgical debridement in the U.S. market. The Company's strategy is to market a range of products to effect a complete wound healing protocol for surgery. The BoneScalpel with SonicOne Technology is a companion product to the recently announced Hyalomatrix® skin substitute and will be positioned accordingly.
Wound cleansing and debridement procedures done in the Operating Room include trauma cases, burns, and chronic wound cases that have escalated beyond the capabilities of the wound clinic. In concert with the release of the BoneScalpel with SonicOne Technology, the Company has also begun marketing a comprehensive line of specialty disposables.
The stand-alone SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures. The Company believes that the SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.
The stand-alone BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. It offers the convenience and speed of a power instrument while minimizing the potential risks associated with rotary sharps.
"Misonix is excited about entering a new segment of the large and growing wound care market, particularly a segment characterized by significant use of high tech disposables," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "We are also pleased with the additional use of an existing product platform, which should lead to manufacturing economies."
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
Kevin McGrath/Cameron Associates, Inc.
|SOURCE Misonix, Inc.|
Copyright©2010 PR Newswire.
All rights reserved